Fulgent Genetics
Market Cap
US$2.1b
Last Updated
2021/05/07 23:51 UTC
Data Sources
Company Financials +
Executive Summary
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. More Details
Rewards
Risk Analysis
Earnings are forecast to decline by an average of 63.3% per year for the next 3 years
Snowflake Analysis
Flawless balance sheet with proven track record.
Similar Companies
Share Price & News
How has Fulgent Genetics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: FLGT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: FLGT's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
Market Performance
7 Day Return
-3.1%
FLGT
4.0%
US Healthcare
-0.3%
US Market
1 Year Return
350.2%
FLGT
43.7%
US Healthcare
50.2%
US Market
Return vs Industry: FLGT exceeded the US Healthcare industry which returned 44.2% over the past year.
Return vs Market: FLGT exceeded the US Market which returned 51.8% over the past year.
Shareholder returns
| FLGT | Industry | Market | |
|---|---|---|---|
| 7 Day | -3.1% | 4.0% | -0.3% |
| 30 Day | -12.8% | 10.2% | 2.2% |
| 90 Day | -47.3% | 19.2% | 3.8% |
| 1 Year | 350.2%350.2% | 45.5%43.7% | 52.7%50.2% |
| 3 Year | 1,864.2%1,864.2% | 65.1%58.3% | 63.4%53.1% |
| 5 Year | n/a | 112.0%95.8% | 129.6%104.0% |
Long-Term Price Volatility Vs. Market
How volatile is Fulgent Genetics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
Estimating The Intrinsic Value Of Fulgent Genetics, Inc. (NASDAQ:FLGT)1 month ago | Simply Wall St
Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?2 months ago | Simply Wall St
Industry Analysts Just Made A Massive Upgrade To Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Revenue ForecastsValuation
Is Fulgent Genetics undervalued compared to its fair value and its price relative to the market?
4.39x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: FLGT ($74.64) is trading above our estimate of fair value ($53.04)
Significantly Below Fair Value: FLGT is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: FLGT is good value based on its PE Ratio (4.4x) compared to the US Healthcare industry average (23.3x).
PE vs Market: FLGT is good value based on its PE Ratio (4.4x) compared to the US market (20.2x).
Price to Earnings Growth Ratio
PEG Ratio: FLGT's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: FLGT is good value based on its PB Ratio (2.7x) compared to the US Healthcare industry average (3.5x).
Future Growth
How is Fulgent Genetics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
-63.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FLGT's earnings are forecast to decline over the next 3 years (-63.3% per year).
Earnings vs Market: FLGT's earnings are forecast to decline over the next 3 years (-63.3% per year).
High Growth Earnings: FLGT's earnings are forecast to decline over the next 3 years.
Revenue vs Market: FLGT's revenue is expected to decline over the next 3 years (-57.9% per year).
High Growth Revenue: FLGT's revenue is forecast to decline over the next 3 years (-57.9% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if FLGT's Return on Equity is forecast to be high in 3 years time
Past Performance
How has Fulgent Genetics performed over the past 5 years?
97.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FLGT has high quality earnings.
Growing Profit Margin: FLGT became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: FLGT has become profitable over the past 5 years, growing earnings by 97% per year.
Accelerating Growth: FLGT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: FLGT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (39.8%).
Return on Equity
High ROE: FLGT's Return on Equity (52%) is considered outstanding.
Financial Health
How is Fulgent Genetics's financial position?
Financial Position Analysis
Short Term Liabilities: FLGT's short term assets ($913.9M) exceed its short term liabilities ($197.5M).
Long Term Liabilities: FLGT has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: FLGT is debt free.
Reducing Debt: FLGT had no debt 5 years ago.
Debt Coverage: FLGT has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: FLGT has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is Fulgent Genetics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate FLGT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FLGT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if FLGT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FLGT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of FLGT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.7yrs
Average management tenure
CEO
Ming Hsieh (64 yo)
5yrs
Tenure
US$248,000
Compensation
Mr. Ming Hsieh has been an Independent Director of Fortinet, Inc. since April 2013. He is the Founder of Fulgent Genetics, Inc. and has been its President & Chief Executive Officer since May 2016 and serve...
CEO Compensation Analysis
Compensation vs Market: Ming's total compensation ($USD248.00K) is below average for companies of similar size in the US market ($USD3.76M).
Compensation vs Earnings: Ming's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: FLGT's management team is considered experienced (4.7 years average tenure).
Board Members
Experienced Board: FLGT's board of directors are considered experienced (4.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: FLGT insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 33.6%.
Top Shareholders
Company Information
Fulgent Genetics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Fulgent Genetics, Inc.
- Ticker: FLGT
- Exchange: NasdaqGM
- Founded: 2011
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$2.117b
- Shares outstanding: 28.99m
- Website: https://www.fulgentgenetics.com
Number of Employees
Location
- Fulgent Genetics, Inc.
- 4978 Santa Anita Avenue
- Temple City
- California
- 91780
- United States
Listings
Biography
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/05/07 23:51 |
| End of Day Share Price | 2021/05/07 00:00 |
| Earnings | 2021/03/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.